Advised Amryt Pharma PLC

ByrneWallace advised Irish-listed pharmaceutical company Amryt Pharma PLC (“Amryt”), on an exclusive in-licence agreement with University College Dublin, for a novel non-viral gene therapy technology platform. 

This unique platform offers a potential treatment to patients with Epidermolysis bullosa ("EB"), and involves the delivery of gene therapy using High Branched Poly (β-Amino Ester) ("HPAE") polymer technology.

Amryt focuses on developing and delivering innovative new treatments which help improve the lives of people with rare and orphan diseases. The Company joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.

For further information on this transaction, please click here.

Colin Sainsbury, Partner and Head of the Life Sciences Group, advised on this transaction.